Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study)

Journal of Clinical Lipidology

Volumn 5, Issue 6, 2011, Pages 474-482

  Robinson, Jennifer G ^a   Ballantyne, Christie M ^b   Hsueh, Willa ^c   Rosen, Jeffrey ^d   Lin, Jianxin ^e   Shah, Arvind ^e   Lowe, Robert S ^e   Hanson, Mary E ^e   Tershakovec, Andrew M ^e  

^a UNIVERSITY OF IOWA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^d Clinical Research of South Florida   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atorvastatin; Ezetimibe simvastatin combination; Hypercholesterolemia; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BODY MASS; CORONARY RISK; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; ATHEROSCLEROSIS; AZETIDINES; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PYRROLES; SIMVASTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 81855164792     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.06.004     Document Type: Article

References (34)

1. S.M. Grundy, J.I. Cleeman, and S.R. Daniels Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 112 2005 2735 2752 (Pubitemid 41532612)
2. C.J. Girman, T. Rhodes, and M. Mercuri The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Am J Cardiol 93 2004 136 141 (Pubitemid 38058719)
3. A.S. Gami, B.J. Witt, and D.E. Howard Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies J Am Coll Cardiol 49 2007 403 414 (Pubitemid 46135879)
4. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
5. I. Graham, D. Atar, and K. Borch-Johnsen European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil 14 2007 S1 113
6. J.G. Robinson, S.F. Wang, B.J. Smith, and T.A. Jacobson Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk J Am Coll Cardiol 53 2009 316 322
7. J.J. Kastelein, W.A. van der Steeg, and I. Holme Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation 117 2008 3002 3009
8. J.D. Brunzell, M. Davidson, and C.D. Furberg Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care 31 2008 811 822
9. S.W. Altmann, H.R. Davis Jr. , and L.J. Zhu Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption Science 303 2004 1201 1204 (Pubitemid 38233587)
10. J.G. Robinson, C.M. Ballantyne, and S.M. Grundy Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study) Am J Cardiol 103 2009 1694 1702
11. S.C. Smith Jr. , J. Allen, and S.N. Blair AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363 2372 (Pubitemid 43947981)
12. O. Miettinen, and M. Nurminen Comparative analysis of two rates Stat Med 4 1985 213 226 (Pubitemid 15055349)
13. N. Abate, A.L. Catapano, and C.M. Ballantyne Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: results of two subgroup analyses J Clin Lipidol 2 2008 91 105 (Pubitemid 351372954)
14. M. Denke, T. Pearson, P. McBride, R.A. Gazzara, W.E. Brady, and A.M. Tershakovec Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome Diab Vasc Dis Res 3 2006 93 102 (Pubitemid 44638383)
15. T. Feldman, L. Ose, and A. Shah Efficacy and safety of ezetimibe/simvastatin versus simvastatin monotherapy in hypercholesterolemic patients with metabolic syndrome Metab Syndr Relat Disord 5 2007 13 21 (Pubitemid 46641419)
16. L. Simons, M. Tonkon, and L. Masana Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome Curr Med Res Opin 20 2004 1437 1445 (Pubitemid 39361347)
17. Vytorin (ezetimibe/simvastatin) [package insert] 2009 Merck/Schering-Plough Pharmaceuticals North Wales, PA
18. Lipitor (atorvastatin calcium) tablets [package insert] 2007 Parke-Davis New York, NY
19. A.B. Polis, N. Abate, and A.L. Catapano Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program Risk Category Metab Syndr Rel Disord 7 2009 601 610
20. K. Tunceli, S.G. Sajjan, and D.R. Ramey Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients J Clin Lipidol 4 2010 491 500
21. C.M. Ballantyne, J.S. Raichlen, and V.A. Cain Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial J Am Coll Cardiol 52 2008 626 632
22. D.C. Chan, and G.F. Watts Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies Expert Opin Pharmacother 12 2011 13 30
23. M. Davidson A Review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome Am J Cardiol 102 2008 19L 27L
24. A.D. Sniderman Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice J Clin Lipidol 2 2008 36 42 (Pubitemid 351250867)
25. J.D. Brunzell, and A.F. Ayyobi Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus Am J Med 115 2003 24 28 (Pubitemid 37532888)
26. C.M. Ballantyne, and V. Nambi Markers of inflammation and their clinical significance Atheroscler Suppl 6 2005 21 29
27. T.A. Pearson, G.A. Mensah, and R.W. Alexander Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511 (Pubitemid 36158056)
28. E.Y. Yang, V. Nambi, and Z. Tang Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population. Insights from the ARIC (Atherosclerosis Risk in Communities) study J Am Coll Cardiol 54 2009 2388 2395
29. S. Devaraj, U. Singh, and I. Jialal Human C-reactive protein and the metabolic syndrome Curr Opin Lipidol 20 2009 182 189
30. M.K. Rutter, J.B. Meigs, L.M. Sullivan, R.B. D'Agostino Sr., and P.W. Wilson C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study Circulation 110 2004 380 385 (Pubitemid 38993845)
31. E.S. Ford The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey Atherosclerosis 168 2003 351 358 (Pubitemid 36703335)
32. P.M. Ridker, J.E. Buring, N.R. Cook, and N. Rifai C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14 719 initially healthy American women Circulation 107 2003 391 397
33. J. Genest, R. McPherson, and J. Frohlich 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations Can J Cardiol 25 2009 567 579
34. G.F. Gensini, A.M. Gori, and B. Dilaghi Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study Int J Cardiol 142 2010 257 264